Narendran Parth, Mannering Stuart I, Harrison Leonard C
The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, 3050 Parkville, Australia.
Autoimmun Rev. 2003 Jun;2(4):204-10. doi: 10.1016/s1568-9972(03)00009-0.
Type 1 diabetes (T1D) is an autoimmune disease characterised by immunity to pancreatic beta-cell autoantigens, associated with beta-cell destruction leading to insulin deficiency and hyperglycaemia. The rigorous definition of an autoimmune disease requires evidence that an autoantigen elicits pathological immune responses. Using criteria for the pathogenicity of an autoantigen, we examine the evidence for proinsulin as an autoantigen in T1D. We conclude that proinsulin satisfies these criteria. As a corollary, proinsulin is a potential immunotherapeutic tool for the prevention of T1D.
1型糖尿病（T1D）是一种自身免疫性疾病，其特征是对胰腺β细胞自身抗原产生免疫反应，伴有β细胞破坏，导致胰岛素缺乏和高血糖症。自身免疫性疾病的严格定义需要有证据表明自身抗原引发了病理性免疫反应。我们使用自身抗原致病性的标准，来检验胰岛素原作为T1D中自身抗原的证据。我们得出结论，胰岛素原符合这些标准。由此推论，胰岛素原是预防T1D的一种潜在免疫治疗工具。
